BioCentury | Feb 15, 2019
Financial News

TCR2 raises $75M in IPO

...and one for a hematological program, by early 2020. Shareholders in TCR2 include MPM Capital, F2 Capital...
BioCentury | Feb 14, 2019
Financial News

TCR2 prices $75M IPO at midpoint

...and one for a hematological program, by early 2020. Shareholders in TCR2 include MPM Capital, F2 Capital...
BioCentury | Jan 4, 2019
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...TC-220 to treat Mucin 16 (MUC16; CA125)-positive solid tumors in early 2020. MPM Capital and F2 Capital...
BioCentury | Dec 28, 2018
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...TC-220 to treat mucin 16 (MUC16; CA125)-positive solid tumors in early 2020. MPM Capital and F2 Capital...
BioCentury | Mar 16, 2015
Finance

Chiasma's private decision

...fund. New investors Rock Springs Capital and Sofinnova Ventures participated, along with existing investors MPM, F2 Capital...
BioCentury | Mar 2, 2015
Financial News

Chiasma completes venture financing

...2015-02-27 Type: Venture financing Raised: $70 million Investors: Rock Springs Capital; Sofinnova Ventures; MPM Capital; F2 Capital...
BioCentury | Feb 28, 2015
Financial News

Chiasma closes $70M series E round

...New investors Rock Springs Capital and Sofinnova Ventures participated, as did existing investors MPM Capital; F2 Capital...
Items per page:
1 - 7 of 7
BioCentury | Feb 15, 2019
Financial News

TCR2 raises $75M in IPO

...and one for a hematological program, by early 2020. Shareholders in TCR2 include MPM Capital, F2 Capital...
BioCentury | Feb 14, 2019
Financial News

TCR2 prices $75M IPO at midpoint

...and one for a hematological program, by early 2020. Shareholders in TCR2 include MPM Capital, F2 Capital...
BioCentury | Jan 4, 2019
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...TC-220 to treat Mucin 16 (MUC16; CA125)-positive solid tumors in early 2020. MPM Capital and F2 Capital...
BioCentury | Dec 28, 2018
Financial News

TCR2 seeks IPO as first program slated to enter clinic

...TC-220 to treat mucin 16 (MUC16; CA125)-positive solid tumors in early 2020. MPM Capital and F2 Capital...
BioCentury | Mar 16, 2015
Finance

Chiasma's private decision

...fund. New investors Rock Springs Capital and Sofinnova Ventures participated, along with existing investors MPM, F2 Capital...
BioCentury | Mar 2, 2015
Financial News

Chiasma completes venture financing

...2015-02-27 Type: Venture financing Raised: $70 million Investors: Rock Springs Capital; Sofinnova Ventures; MPM Capital; F2 Capital...
BioCentury | Feb 28, 2015
Financial News

Chiasma closes $70M series E round

...New investors Rock Springs Capital and Sofinnova Ventures participated, as did existing investors MPM Capital; F2 Capital...
Items per page:
1 - 7 of 7